China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

SZSE:000999 Stock Report

Market Cap: CN¥59.3b

China Resources Sanjiu Medical & Pharmaceutical Future Growth

Future criteria checks 1/6

China Resources Sanjiu Medical & Pharmaceutical is forecast to grow earnings and revenue by 12.3% and 10% per annum respectively. EPS is expected to grow by 12.1% per annum. Return on equity is forecast to be 16.3% in 3 years.

Key information

12.3%

Earnings growth rate

12.1%

EPS growth rate

Pharmaceuticals earnings growth19.0%
Revenue growth rate10.0%
Future return on equity16.3%
Analyst coverage

Good

Last updated28 Apr 2024

Recent future growth updates

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 23
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Apr 23
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued

Apr 16
An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued

Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings

Mar 20
Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings

Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?

Feb 28
Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?

Earnings and Revenue Growth Forecasts

SZSE:000999 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202633,5414,2844,5445,56810
12/31/202531,2353,7924,0644,62014
12/31/202427,5603,2984,1205,31610
3/31/202425,6813,0663,8974,677N/A
12/31/202324,7392,8533,3354,192N/A
9/30/202324,5772,8993,0684,039N/A
6/30/202322,8252,8931,8542,876N/A
3/31/202320,1822,7591,8562,858N/A
1/1/202318,0792,4492,0553,006N/A
9/30/202216,3932,2511,5992,448N/A
6/30/202216,0812,1121,9192,734N/A
3/31/202215,7152,2531,2542,055N/A
1/1/202215,5442,0551,0121,885N/A
9/30/202115,5861,7731,2992,133N/A
6/30/202115,6231,9191,4892,213N/A
3/31/202114,5561,7171,1121,857N/A
12/31/202013,6371,5971,6022,224N/A
9/30/202013,9201,7101,3461,976N/A
6/30/202013,5051,4311,2031,828N/A
3/31/202014,4731,4551,7412,263N/A
12/31/201914,7942,0991,4111,949N/A
9/30/201914,1712,2891,4471,906N/A
6/30/201914,1222,3281,5172,012N/A
3/31/201913,5302,1761,3962,009N/A
12/31/201813,4281,4321,3111,911N/A
9/30/201813,0801,4551,3581,943N/A
6/30/201812,5941,3871,3971,906N/A
3/31/201812,0431,3501,2871,697N/A
12/31/201711,1201,302N/A1,599N/A
9/30/201710,3011,288N/A1,577N/A
6/30/20179,6991,303N/A1,459N/A
3/31/20179,3071,260N/A1,347N/A
12/31/20168,9821,198N/A1,392N/A
9/30/20168,5531,290N/A1,335N/A
6/30/20168,4851,258N/A1,320N/A
3/31/20168,1491,223N/A1,341N/A
12/31/20157,9001,249N/A1,260N/A
9/30/20157,7091,160N/A1,338N/A
6/30/20157,4751,107N/A1,330N/A
3/31/20157,4121,086N/A1,213N/A
12/31/20147,2771,036N/A1,184N/A
9/30/20146,770938N/A1,105N/A
6/30/20146,9591,064N/A1,152N/A
3/31/20147,1961,058N/A1,177N/A
12/31/20137,2931,109N/A1,345N/A
9/30/20137,6301,150N/A1,369N/A
6/30/20137,4441,102N/A1,535N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 000999's forecast earnings growth (12.3% per year) is above the savings rate (2.9%).

Earnings vs Market: 000999's earnings (12.3% per year) are forecast to grow slower than the CN market (24.2% per year).

High Growth Earnings: 000999's earnings are forecast to grow, but not significantly.

Revenue vs Market: 000999's revenue (10% per year) is forecast to grow slower than the CN market (14.7% per year).

High Growth Revenue: 000999's revenue (10% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 000999's Return on Equity is forecast to be low in 3 years time (16.3%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.